Annovis Bio, Inc. announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer's disease (AD). A total of 327 patients have successfully concluded the phase II/III trial out of the initial 353 enrolled.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.785 USD | +13.65% | +45.23% | -58.45% |
05-10 | Annovis Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-09 | Annovis Bio, Inc. Announces Unblinding of the Buntanetap Phase III Data in Parkinson?s Disease | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.45% | 75.43M | |
+4.19% | 111B | |
+11.45% | 105B | |
-12.71% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.43% | 16.96B | |
+3.18% | 13.7B | |
+36.71% | 12.45B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease